Assessing Nektar Therapeutics (NKTR) Valuation After Its Recent Share Price Recovery

Simply Wall St.05-13

AdvertisementWhy Nektar Therapeutics (NKTR) is on investor radar Nektar Therapeutics (NKTR) has drawn fresh attention after recent trading saw the stock move against a backdrop of mixed performance, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635205563?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-05-13 14:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635205563","market":"nz","top_or_hot":-1,"title":"Assessing Nektar Therapeutics (NKTR) Valuation After Its Recent Share Price Recovery","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Nektar Therapeutics (NKTR) is on investor radar Nektar Therapeutics (NKTR) has drawn fresh attention after recent trading saw the stock move against a backdrop of mixed performance, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/assessing-nektar-therapeutics-nktr-valuation-after-its-recen\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Nektar Therapeutics (NKTR) Valuation After Its Recent Share Price Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Nektar Therapeutics (NKTR) Valuation After Its Recent Share Price Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-13 14:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/assessing-nektar-therapeutics-nktr-valuation-after-its-recen><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Nektar Therapeutics (NKTR) is on investor radar Nektar Therapeutics (NKTR) has drawn fresh attention after recent trading saw the stock move against a backdrop of mixed performance, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/assessing-nektar-therapeutics-nktr-valuation-after-its-recen\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/assessing-nektar-therapeutics-nktr-valuation-after-its-recen","article_id":"2635205563","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/assessing-nektar-therapeutics-nktr-valuation-after-its-recen","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2635205563","pubTimestamp":1778655283,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Nektar Therapeutics (NKTR) is on investor radar\nNektar Therapeutics (NKTR) has drawn fresh attention after recent trading saw the stock move against a backdrop of mixed performance, with a modest gain over the past month but a stronger recovery across the past 3 months.\nSee our latest analysis for Nektar Therapeutics.\nAt a latest share price of $78.43, Nektar’s recent pullback over the past week contrasts with an 18.2% 3 month share price return and a very large 1 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NKTR":"内克塔治疗"},"translate_title":"评估Nektar Therapeutics(NKTR)近期股价回升后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":1.5},"content_text":"AdvertisementWhy Nektar Therapeutics (NKTR) is on investor radar Nektar Therapeutics (NKTR) has drawn fresh attention after recent trading saw the stock move against a backdrop of mixed performance, with a modest gain over the past month but a stronger recovery across the past 3 months. See our latest analysis for Nektar Therapeutics. At a latest share price of $78.43, Nektar’s recent pullback over the past week contrasts with an 18.2% 3 month share price return and a very large 1 year total shareholder return. Together, these figures suggest sentiment has shifted meaningfully compared with its longer term track record. If you are looking beyond a single biotech stock, this could be a useful moment to size up other healthcare focused opportunities using our screener of 33 healthcare AI stocks With Nektar’s share price already up strongly over the past year but still trading at a very large discount to the consensus price target, you have to ask: is there real upside left here, or is the market already pricing in future growth? Most Popular Narrative: 46% Undervalued At a last close of $78.43 against a fair value estimate of $144.25, the most followed Nektar narrative frames the recent rally as only part of the story.  Robust cash position after the recent equity raise extends runway into 2027, providing operational stability to advance late-stage assets and initiate Phase III trials without near-term dilution or financing risk. This supports earnings predictability and reduces financial leverage concerns.  Read the complete narrative. Curious what has to happen between now and 2029 for that fair value to make sense? Revenue paths, margin shifts and a very demanding earnings multiple all sit at the core of this narrative. Result: Fair Value of $144.25 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on rezpegaldesleukin delivering in larger Phase 3 trials and on Nektar managing ongoing losses without relying heavily on fresh equity funding. Find out about the key risks to this Nektar Therapeutics narrative. Another Way to Look at Nektar’s Valuation The analyst narrative points to a fair value of $144.25, yet Nektar trades on a P/S of 47.6x versus 4.8x for the US pharmaceuticals sector and a fair ratio of 19.4x. That big gap raises a simple question: is the upside story already embedded in today’s rich multiple? See what the numbers say about this price — find out in our valuation breakdown. NasdaqCM:NKTR P/S Ratio as at May 2026Next Steps Mixed signals so far, with strong optimism but clear concerns in the background, so check the data yourself, weigh both sides, and see the 1 key reward and 3 important warning signs Looking for more investment ideas? If Nektar has caught your attention, do not stop there. Use this momentum to broaden your watchlist and pressure test your next moves across other opportunities.  Spot potential value by scanning a focused list of quality companies trading below their estimated worth with the help of 44 high quality undervalued stocks. Prioritise resilience by reviewing 69 resilient stocks with low risk scores that score well on stability, financial strength, and lower overall risk profiles. Hunt for tomorrow’s potential standouts before they hit the headlines with a screener containing 22 high quality undiscovered gems that filters for strong fundamentals.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Nektar Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635205563","isCrawlerRequest":true}